Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16,346 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Direct and Indirect Effect of Guselkumab on Anxiety, Depression, and Quality of Life in Patients with Moderate-to-Severe Plaque Psoriasis: A Mediation Analysis.
Armstrong AW, Foley P, Liu Y, Miller M, Teneralli RE, Bewley A, Gordon KB, Papp KA, Han C. Armstrong AW, et al. Among authors: miller m. Dermatol Ther (Heidelb). 2024 Sep;14(9):2577-2589. doi: 10.1007/s13555-024-01250-9. Epub 2024 Aug 23. Dermatol Ther (Heidelb). 2024. PMID: 39177870 Free PMC article.
Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2.
Reich K, Gordon KB, Strober BE, Armstrong AW, Miller M, Shen YK, You Y, Han C, Yang YW, Foley P, Griffiths CEM. Reich K, et al. Among authors: miller m. Br J Dermatol. 2021 Dec;185(6):1146-1159. doi: 10.1111/bjd.20568. Epub 2021 Sep 8. Br J Dermatol. 2021. PMID: 34105767 Clinical Trial.
Consistent safety profile with up to 5 years of continuous treatment with guselkumab: Pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis.
Blauvelt A, Tsai TF, Langley RG, Miller M, Shen YK, You Y, Yang YW, Papp KA, Puig L. Blauvelt A, et al. Among authors: miller m. J Am Acad Dermatol. 2022 Apr;86(4):827-834. doi: 10.1016/j.jaad.2021.11.004. Epub 2021 Nov 17. J Am Acad Dermatol. 2022. PMID: 34798201 Clinical Trial.
Super-response to guselkumab treatment in patients with moderate-to-severe psoriasis: age, body weight, baseline Psoriasis Area and Severity Index, and baseline Investigator's Global Assessment scores predict complete skin clearance.
Reich K, Gordon KB, Strober B, Langley RG, Miller M, Yang YW, Shen YK, You Y, Zhu Y, Foley P, Blauvelt A. Reich K, et al. Among authors: miller m. J Eur Acad Dermatol Venereol. 2022 Dec;36(12):2393-2400. doi: 10.1111/jdv.18474. Epub 2022 Aug 22. J Eur Acad Dermatol Venereol. 2022. PMID: 35920762
Malignancy rates through 5 years of follow-up in patients with moderate-to-severe psoriasis treated with guselkumab: Pooled results from the VOYAGE 1 and VOYAGE 2 trials.
Blauvelt A, Lebwohl M, Langley RG, Rowland K, Yang YW, Chan D, Miller M, You Y, Yu J, Thaҫi D, Foley P, Papp KA. Blauvelt A, et al. Among authors: miller m. J Am Acad Dermatol. 2023 Aug;89(2):274-282. doi: 10.1016/j.jaad.2023.03.035. Epub 2023 Apr 3. J Am Acad Dermatol. 2023. PMID: 37019386 Free article.
16,346 results
You have reached the last available page of results. Please see the User Guide for more information.